JO3793B1 - مثبطات تيروزين كاينيز بروتون وأساليب استخدامها - Google Patents

مثبطات تيروزين كاينيز بروتون وأساليب استخدامها

Info

Publication number
JO3793B1
JO3793B1 JOP/2016/0257A JOP20160257A JO3793B1 JO 3793 B1 JO3793 B1 JO 3793B1 JO P20160257 A JOP20160257 A JO P20160257A JO 3793 B1 JO3793 B1 JO 3793B1
Authority
JO
Jordan
Prior art keywords
methods
bruton
inhibitors
tyrosine kinase
compounds
Prior art date
Application number
JOP/2016/0257A
Other languages
English (en)
Inventor
Zhang Zheng
P Edwards James
Ghosh Brahmananda
Kent Barbay Joseph
Li Gang
J M Wiener John
Arora Nidhi
S Tichenor Mark
D Bembenek Scott
Pooley Deckhut Charlotte
Cai Min
Xiao Kun
Hao Baoyu
M Bacani Genesis
D Kreutter Kevin
Wei Jianmei
Chen Wei
D Venable Jennifer
Wu Yao
Zhang Feihuang
Zhu Yaoping
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3793B1 publication Critical patent/JO3793B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

الاختراع الحالي موجه لمركبات الصيغة I وأساليب استخدامها وتحضيرها، فضلاً عن التركيبات التي تتكون منها مركبات الصيغة I.
JOP/2016/0257A 2015-12-10 2016-12-08 مثبطات تيروزين كاينيز بروتون وأساليب استخدامها JO3793B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
JO3793B1 true JO3793B1 (ar) 2021-01-31

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0257A JO3793B1 (ar) 2015-12-10 2016-12-08 مثبطات تيروزين كاينيز بروتون وأساليب استخدامها

Country Status (16)

Country Link
US (3) US10689396B2 (ar)
EP (1) EP3386992B1 (ar)
JP (1) JP7110097B2 (ar)
KR (1) KR20180094514A (ar)
CN (2) CN109071563A (ar)
AR (1) AR107041A1 (ar)
AU (1) AU2016366546B2 (ar)
BR (1) BR112018011525B1 (ar)
CA (1) CA3007993C (ar)
EA (1) EA038031B1 (ar)
IL (1) IL259862B (ar)
JO (1) JO3793B1 (ar)
MX (1) MX2018007084A (ar)
TW (1) TWI739779B (ar)
UY (1) UY37016A (ar)
WO (1) WO2017100668A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
TW202039512A (zh) 2018-12-06 2020-11-01 日商第一三共股份有限公司 環烷-1,3-二胺化合物
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎（南京）医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US7659284B2 (en) 2004-09-15 2010-02-09 Janssen Pharmaceutica Nv Thiazolopyridine kinase inhibitors
WO2006118749A1 (en) 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
CN101277689B (zh) 2005-08-08 2011-01-12 詹森药业有限公司 噻唑并嘧啶类激酶抑制剂
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
HUE058914T2 (hu) 2013-03-15 2022-09-28 Janssen Pharmaceutica Nv Gyógyszer elõállítására szolgáló eljárások és köztitermékek
LT3080103T (lt) * 2013-12-11 2018-08-10 Biogen Ma Inc. Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CA3007993A1 (en) 2017-06-15
BR112018011525B1 (pt) 2023-10-24
EP3386992A1 (en) 2018-10-17
EA201891379A1 (ru) 2018-12-28
TWI739779B (zh) 2021-09-21
CN113105475A (zh) 2021-07-13
EP3386992B1 (en) 2019-11-27
US10800792B2 (en) 2020-10-13
CN113105475B (zh) 2022-09-09
AR107041A1 (es) 2018-03-14
UY37016A (es) 2017-06-30
AU2016366546A1 (en) 2018-05-31
JP7110097B2 (ja) 2022-08-01
MX2018007084A (es) 2018-11-09
CN109071563A (zh) 2018-12-21
AU2016366546B2 (en) 2021-08-12
US20190284204A1 (en) 2019-09-19
JP2018536684A (ja) 2018-12-13
IL259862B (en) 2022-04-01
BR112018011525A2 (pt) 2018-11-21
JP2022141851A (ja) 2022-09-29
TW201734020A (zh) 2017-10-01
US10689396B2 (en) 2020-06-23
US20190284203A1 (en) 2019-09-19
US10822348B2 (en) 2020-11-03
EA038031B1 (ru) 2021-06-25
IL259862A (en) 2018-07-31
CA3007993C (en) 2024-01-16
US20170283431A1 (en) 2017-10-05
WO2017100668A1 (en) 2017-06-15
KR20180094514A (ko) 2018-08-23

Similar Documents

Publication Publication Date Title
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EA201790418A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA201992728A1 (ru) Ингибиторы киназы и способы их применения
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.